Related Experiment Videos
[Immunocorrective therapy of pyelonephritis in children]
Insights
Tactivin, an immunomodulatory polypeptide drug, effectively treated pyelonephritis in children, improving clinical and lab markers. This immunological treatment demonstrated significant efficacy with no observed side effects.
Area of Science:
- Immunology
- Pediatric Nephrology
Context:
- Pyelonephritis is a significant kidney infection in children.
- Immunological treatments offer potential therapeutic avenues.
Purpose:
- To evaluate the efficacy and safety of tactivin, a polypeptide drug, in treating acute and chronic pyelonephritis in children.
Summary:
- A study involving 40 children with pyelonephritis showed that 82.5% experienced clinical and laboratory improvements with tactivin treatment.
- Improvements included reduced proteinuria, normalized urinary sedimentation, and decreased bacteriuria, indicating enhanced resistance to infection.
- While 15% had persistent leukocyturia, disease progression was still hindered, and no adverse effects were reported.
Impact:
- Tactivin administration stimulated humoral immune response and complement system activation.
- The drug enhanced T-lymphocyte competence, contributing to favorable disease pathogenesis in pediatric pyelonephritis.
- This study highlights tactivin as a potentially valuable agent in the combined treatment of pediatric kidney infections.
Abstract:
A total of 40 children who suffered from acute or chronic pyelonephritis underwent immunological treatment with polypeptide drug tactivin. There was an evidence of clinical and laboratory improvement in 82.5 per cent of treated persons, first manifest in decreased proteinuria and normalized urinary sedimentation, and then in lower levels of bacteriuria due to the developing resistance to infectious agents. In 15 per cent of tactivin-treated children leukocyturia persisted though the disease progression was hindered. In the course of the treatment no side-effects were noted. In line with the stimulation of humoral immune response and activation of the complement system, tactivin administration evoked the competence of T-lymphocytes and potentiated the development of this link of immune system. As part of combined treatment the above preparation favourably affected the disease pathogenesis in children.